Hanover - Delayed Quote EUR

Novo Nordisk A/S (NOV.HA)

53.60

-1.46

(-2.65%)

As of 10:04:34 AM GMT+2. Market Open.

The Best Stock to Buy With Less Than $60 in the Market Sell-Off

One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for just $60 each, and as recently as last July, traded in the mid-140s. Novo Nordisk is an outstanding business to own for this amount, even considering the recent issues it has faced. There can also be disadvantages in overreliance on a single therapeutic area, and Novo Nordisk has long focused on endocrine-related disorders.

Motley Fool 2 hours ago

NVO

LLY
Trending tickers: Alphabet, Intel, Meta, Novo Nordisk and WPP

The latest investor updates on stocks that are trending on Friday.

Yahoo Finance UK 2 hours ago

GOOG

LLY

META
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.

Zacks 20 hours ago

NVO

LLY
Novo Nordisk's stellar Wegovy-fuelled run of hiking sales guidance could be ending

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which helped make Novo Europe's most valuable listed company worth $615 billion at its peak, is coming to an end. Half a dozen analysts and investors say even that may no longer be realistic and the company could cut the guidance when it releases first-quarter results on May 7.

Reuters yesterday

NVO
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results -- though strong by comparison to most of its peers -- haven't been as good as investors expected. The company has also faced clinical trial setbacks: An otherwise promising weight loss medicine it developed failed to impress the market with its late-stage results.

Motley Fool 2 days ago

NVO

LLY
Is Eli Lilly Stock a Buy?

The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.

Motley Fool 2 days ago

LLY

NVO
Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Investor's Business Daily 2 days ago

PFE

LLY

NONOF
Novo Nordisk (NVO) Is a Good Short-Term Pick, Wealth Manager Says

Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the founder and principal of Walser Wealth Management, told Schwab Network recently. Walser also identified semiconductor equipment maker Lam Research (LRCX) as a good pick for the near term. Why Walser Is Bullish on NVO NVO is […]

Insider Monkey 2 days ago

NVO

LRCX
Why Novo Nordisk Stock Popped Today

Novo Nordisk has a GLP-1 Ozempic pill. That's both good and bad news for Novo Nordisk stock.

Motley Fool 2 days ago

NVO
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), the once-obscure Danish company that earned the first U.S. Food and Drug Administration (FDA) approval for such treatments with its Wegovy back in mid-2021. Novo Nordisk bears would be quick to point a paw at the company's so far sole competitor in the GLP-1 race, Eli Lilly.

Motley Fool 2 days ago

NVO
Trending tickers: Nvidia, Tesla, Roche, Novo Nordisk and Fresnillo

The latest investor updates on stocks that are trending on Tuesday.

Yahoo Finance UK 3 days ago

^GSPC

^FTSE

^IXIC
Novo shares down on Eli Lilly’s positive obesity pill data

Investing.com -- Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and blood sugar control comparable to injectable treatments like Ozempic.

Investing.com 3 days ago

LLY

NVO

PFE
Novo Nordisk Drops on Weight-Loss Study by Rival Lilly

Novo Nordisk slumped after a pill from rival Eli Lilly helped patients shed weight and control blood sugar about as well as its injected blockbuster Ozempic. Bloomberg Intelligence's Sam Fazeli explains.

Bloomberg 3 days ago

LLY

NVO
Is Novo Nordisk A/S (NVO) The Top Falling Stock with Unusual Volume?

We recently published a list of Top 20 Falling Stocks with Unusual Volume. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other top falling stocks with unusual volume. Uncertainty around tariffs and macroeconomic conditions has dented investor confidence, resulting in stock prices falling. While some […]

Insider Monkey 3 days ago

NVO
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note

Novo Nordisk (NVO) closed the most recent trading day at $58.33, moving +0.43% from the previous trading session.

Zacks 3 days ago

NVO

^GSPC
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Is it time to buy the dip in Novo Nordisk stock? With a history dating back more than 100 years, Novo Nordisk has long been a leader in diabetes care.

Motley Fool 3 days ago

NVO

LLY
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Zacks 3 days ago

NVO
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.

Zacks 3 days ago

LLY

VKTX

NVO
Did Eli Lilly Just Say Checkmate to Novo Nordisk?

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight loss -- but doctors have prescribed either for weight management. It soon was joined by Eli Lilly (NYSE: LLY), selling similar drugs -- the molecule tirzepatide, approved in 2022 under the name Mounjaro for the diabetes indication and approved a year later as Zepbound for weight loss.

Motley Fool 4 days ago

LLY

NVO
Can anything threaten Novo and Lilly’s obesity market dominance?

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

Pharma Voice 4 days ago

LLY

NVO

Performance Overview

Return	NOV.HA	OMX Copenhagen 25 Index (^OMXC25)
YTD	-26.76%	-10.05%
1-Year	-45.92%	-15.82%
3-Year	+49.96%	-8.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NOV.HA)

The Best Stock to Buy With Less Than $60 in the Market Sell-Off

Trending tickers: Alphabet, Intel, Meta, Novo Nordisk and WPP

Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

Novo Nordisk's stellar Wegovy-fuelled run of hiking sales guidance could be ending

Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?

Is Eli Lilly Stock a Buy?

Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill

Novo Nordisk (NVO) Is a Good Short-Term Pick, Wealth Manager Says

Why Novo Nordisk Stock Popped Today

Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.

Trending tickers: Nvidia, Tesla, Roche, Novo Nordisk and Fresnillo

Novo shares down on Eli Lilly’s positive obesity pill data

Novo Nordisk Drops on Weight-Loss Study by Rival Lilly

Is Novo Nordisk A/S (NVO) The Top Falling Stock with Unusual Volume?

Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note

Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Did Eli Lilly Just Say Checkmate to Novo Nordisk?

Can anything threaten Novo and Lilly’s obesity market dominance?

Performance Overview